Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + T-DM1 in HER2+ Breast Cancer
NCT04042051Phase 1Terminated
- Sponsor
- Cancer Trials Ireland
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of copanlisib in HER2-positive breast cancer, sponsored by Cancer Trials Ireland. Primary endpoint: Incidence of Dose Limiting Toxicity at 1.5 years. Started Nov 2019; status: terminated.
02
Drugs
copanlisib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04042051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042051.